NasdaqCM:BLFS

Stock Analysis Report

Executive Summary

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States.


Snowflake Analysis

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has BioLife Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLFS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.2%

BLFS

-1.6%

US Medical Equipment

-2.6%

US Market


1 Year Return

-42.8%

BLFS

-5.2%

US Medical Equipment

-13.3%

US Market

Return vs Industry: BLFS underperformed the US Medical Equipment industry which returned -7.7% over the past year.

Return vs Market: BLFS underperformed the US Market which returned -15.9% over the past year.


Shareholder returns

BLFSIndustryMarket
7 Day8.2%-1.6%-2.6%
30 Day-26.4%-10.2%-15.2%
90 Day-38.8%-17.5%-22.2%
1 Year-42.8%-42.8%-4.4%-5.2%-11.5%-13.3%
3 Year406.9%406.9%45.4%41.5%13.2%5.7%
5 Year343.5%343.5%75.2%57.1%31.8%17.2%

Price Volatility Vs. Market

How volatile is BioLife Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioLife Solutions undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BLFS ($9.84) is trading below our estimate of fair value ($48.86)

Significantly Below Fair Value: BLFS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLFS is good value based on its PE Ratio (17.3x) compared to the Medical Equipment industry average (37.5x).

PE vs Market: BLFS is poor value based on its PE Ratio (17.3x) compared to the US market (12.2x).


Price to Earnings Growth Ratio

PEG Ratio: BLFS is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: BLFS is good value based on its PB Ratio (2.4x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is BioLife Solutions forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

31.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLFS's forecast earnings growth (31.6% per year) is above the savings rate (1.7%).

Earnings vs Market: BLFS's earnings (31.6% per year) are forecast to grow faster than the US market (13.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BLFS's revenue (28.2% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: BLFS's revenue (28.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BLFS's Return on Equity is forecast to be low in 3 years time (12%).


Next Steps

Past Performance

How has BioLife Solutions performed over the past 5 years?

56.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLFS has a high level of non-cash earnings.

Growing Profit Margin: BLFS's current net profit margins (40.4%) are higher than last year (14.8%).


Past Earnings Growth Analysis

Earnings Trend: BLFS has become profitable over the past 5 years, growing earnings by 56.4% per year.

Accelerating Growth: BLFS's earnings growth over the past year (277.9%) exceeds its 5-year average (56.4% per year).

Earnings vs Industry: BLFS earnings growth over the past year (277.9%) exceeded the Medical Equipment industry 1%.


Return on Equity

High ROE: BLFS's Return on Equity (13.3%) is considered low.


Next Steps

Financial Health

How is BioLife Solutions's financial position?


Financial Position Analysis

Short Term Liabilities: BLFS's short term assets ($24.2M) exceed its short term liabilities ($7.8M).

Long Term Liabilities: BLFS's short term assets ($24.2M) exceed its long term liabilities ($2.2M).


Debt to Equity History and Analysis

Debt Level: BLFS is debt free.

Reducing Debt: BLFS had no debt 5 years ago.

Debt Coverage: BLFS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BLFS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BioLife Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLFS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLFS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLFS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLFS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Mike Rice (56yo)

13.67s

Tenure

US$691,397

Compensation

Mr. Michael P. Rice, also known as Mike, has been Chief Executive Officer and President of BioLife Solutions, Inc. since August 2006. Mr. Rice has more than 30 years of leadership and entrepreneurial exper ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD691.40K) is below average for companies of similar size in the US market ($USD1.51M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Rice
President13.67yrsUS$691.40k1.05% $2.2m
Roderick de Greef
CFO, COO & Secretary3.92yrsUS$490.00k0.28% $597.6k
Aby Mathew
Chairman of Scientific Advisory Boardno dataUS$511.00k1.04% $2.2m
Kevin O'Donnell
Vice President of Cold Chain Standards5.33yrsno datano data
Todd Berard
Chief Marketing Officer5.17yrsno data0.32% $665.6k
Karen Foster
Chief Quality Officer0.33yrno data0.26% $537.5k
James Mathers
Chief Revenue Officer0.33yrno data0.098% $205.6k

3.9yrs

Average Tenure

57.5yo

Average Age

Experienced Management: BLFS's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Rice
President13.67yrsUS$691.40k1.05% $2.2m
Aby Mathew
Chairman of Scientific Advisory Boardno dataUS$511.00k1.04% $2.2m
Raymond Cohen
Non-Executive Chairman6.42yrsUS$240.00k0.11% $240.7k
Thomas Girschweiler
Director4.92yrsUS$110.00k7.45% $15.7m
Shelly Heimfeld
Member of Scientific Advisory Board13.5yrsno datano data
Scott Burger
Member of Scientific Advisory Board12.58yrsno datano data
Dayong Gao
Member of Scientific Advisory Board13.5yrsno datano data
Joseph Schick
Independent Director6.42yrsUS$120.00k0.034% $70.7k
Andrew Hinson
Independent Director & Member of the Scientific Advisory Board13.17yrsUS$115.00k0.071% $148.8k
Erik Woods
Member of Scientific Advisory Board12.58yrsno datano data

12.6yrs

Average Tenure

57yo

Average Age

Experienced Board: BLFS's board of directors are seasoned and experienced ( 12.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BLFS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.


Top Shareholders

Company Information

BioLife Solutions, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioLife Solutions, Inc.
  • Ticker: BLFS
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$210.453m
  • Shares outstanding: 20.45m
  • Website: https://www.biolifesolutions.com

Number of Employees


Location

  • BioLife Solutions, Inc.
  • 3303 Monte Villa Parkway
  • Suite 310
  • Bothell
  • Washington
  • 98021
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLFSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 1989
BJX1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1989

Biography

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 03:26
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.